



(51) International Patent Classification:

A61K 9/00 (2006.01) A61P 15/18 (2006.01)

A61K 31/567 (2006.01) A61F 6/06 (2006.01)

A61K 31/57 (2006.01)

(21) International Application Number:

PCT/US2020/038568

(22) International Filing Date:

19 June 2020 (19.06.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

16/448,399 21 June 2019 (21.06.2019) US

(71) Applicant: THE POPULATION COUNCIL, INC.

[US/US]; One Dag Hammarskjold Plaza, New York, New York 10017 (US).

(72) Inventor: VARIANO, Bruce; c/o THE POPULATION

COUNCIL, INC., One Dag Hammarskjold Plaza, New York, New York 10017 (US).

(74) Agent: BODENSTEIN, Matthew et al.; STERNE,

KESSLER, GOLDSTEIN & FOX P.L.L.C, 1100 New York

Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every


kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: SYSTEM FOR PROVIDING BIRTH CONTROL

FIG. 1A



(57) Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*